Related Experiment Video
Updated: Oct 30, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
Tania Crombet Ramos1, Orestes Santos Morales1, Grace K Dy2
1Research Direction, Center of Molecular Immunology, Havana, Cuba.
Abstract:
Advanced non-small cell lung cancer (NSCLC) has faced a therapeutic revolution with the advent of tyrosine kinase inhibitors (TKIs) and immune checkpoints inhibitors (ICIs) approved for first and subsequent therapies. CIMAvax-EGF is a chemical conjugate between human-recombinant EGF and P64, a recombinant protein from Neisseria meningitides, which induces neutralizing antibodies against EGF. In the last 15 years, it has been extensively evaluated in advanced NSCLC patients. CIMAvax-EGF is safe, even after extended use, and able to keep EGF serum concentration below detectable levels. In a randomized phase III study, CIMAvax-EGF increased median overall survival of advanced NSCLC patients with at least stable disease after front-line chemotherapy. Patients bearing squamous-cell or adenocarcinomas and serum EGF concentration above 870 pg/ml had better survival compared to control patients treated with best supportive care as maintenance, confirming tumors' sensitivity to the EGF depletion. This manuscript reviews the state-of-the-art NSCLC therapy and proposes the most promising scenarios for evaluating CIMAvax-EGF, particularly in combination with TKIs or ICIs. We hypothesize that the optimal combination of CIMAvax-EGF with established therapies can further contribute to transform advanced cancer into a manageable chronic disease, compatible with years of good quality of life.
Insights
CIMAvax-EGF, a novel therapy, improved survival in advanced non-small cell lung cancer (NSCLC) patients. This immunotherapy shows promise when combined with other treatments for better long-term outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Advanced non-small cell lung cancer (NSCLC) treatments have evolved with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs).
- Epidermal Growth Factor (EGF) plays a role in NSCLC progression.
- CIMAvax-EGF is an immunotherapy that targets EGF by inducing neutralizing antibodies.
Purpose of the Study:
- To review current NSCLC therapies and evaluate CIMAvax-EGF's role.
- To explore potential combinations of CIMAvax-EGF with TKIs and ICIs.
- To assess CIMAvax-EGF's safety and efficacy in advanced NSCLC patients.
Main Methods:
- A randomized phase III study evaluated CIMAvax-EGF as maintenance therapy after front-line chemotherapy.
- Serum EGF concentrations were monitored.
- Overall survival was compared between patients receiving CIMAvax-EGF and best supportive care.
Main Results:
- CIMAvax-EGF demonstrated safety with extended use, maintaining low serum EGF levels.
- A significant increase in median overall survival was observed in advanced NSCLC patients with stable disease post-chemotherapy.
- Patients with squamous-cell or adenocarcinomas and high serum EGF (>870 pg/ml) showed improved survival.
Conclusions:
- CIMAvax-EGF is a safe and effective immunotherapy for advanced NSCLC, particularly in patients with high EGF levels.
- Combining CIMAvax-EGF with TKIs or ICIs presents promising therapeutic strategies.
- The goal is to manage advanced NSCLC as a chronic condition, improving quality of life.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...